Pan-cancer telemedicine registry of immunotherapy responses in patients with structural variations in PD-1 ligands

All Cancers
Researcher Headshot
Sameek Roychowdhury, MD, PhD
The Ohio State University

Summary: 

Cancer cells evolve and develop protective mechanisms to hide themselves from cancer killing T-cells. Immune checkpoint inhibitors (ICIs), block these protective mechanisms by targeting PD-1/PD-L1, unhiding cancer cells so that they can be killed by T-cells. Immune checkpoint inhibitors have revolutionized the treatment of various solid and blood cancers by producing durable responses and improved survival in many cancers. However, there are limited number of biomarkers that predict response to PD-1 ICIs including PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI-H). Thus, there is a need to identify novel biomarkers that may help predict responses to PD-1 ICIs. The study team has identified a number of genomic alterations in PD-L1 and PD-L2 that may be novel predictive biomarkers for response to PD-1 ICIs. This phase II telemedicine trial will investigate whether the genomic alterations in PD-L1 and PD-L2 can help predict a response to pembrolizumab, an ICI, in any cancer patients with these alterations.

Trial Registration: ClinicalTrials.gov Identifier: NCT02090530

Grant Opportunities

Learn more about the spectrum of funding programs from Gateway

Apply For a Grant

Funded Trials

Explore early phase clinical trials currently funded by Gateway
 

Explore Funded Trials

Grant Management

Access grant applications, review submissions and clinical trial progress

Log In Now